Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 3,253 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Subarachnoid Hemorrhage, Aneurysmal
Interventions: - Non-Invasive Near-infrared Spectroscopy (NIRS) device (HEM1 with Foresight Elite Sensor); Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 89 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Dementia With Lewy Bodies
Interventions: Terazosin Hydrochloride, Placebo; Drug · Other
Lead sponsor: Qiang Zhang; Other
Eligibility: 0 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Fibromyalgia
Interventions: Green Light; Device
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: HIV Testing, STI, HCV, Overdose, Drug
Interventions: Sex Trafficking Survivor-Developed Digital Crowdsourced Intervention; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 368 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Spinal Cord Injury, Spinal Cord Disease, Spinal Cord Injuries (SCI)
Interventions: Spinal cord transcutaneous stimulation, Paired spinal cord and peripheral nerve stimulation; Device
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Glioblastoma, Mismatch Repair Deficiency
Interventions: Pembrolizumab, Navifus Focused Ultrasound Sonification; Drug · Device
Lead sponsor: Jennifer Leddon; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Autism Spectrum Disorder
Interventions: Active LIFU; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 13 Years to 25 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Insomnia, Mild Cognitive Impairment
Interventions: Cognitive BehavioralTherapy for Insomnia (CBT-I), SleepSMART; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: San Diego, California

Conditions: Systemic Inflammation (hsCRP), Healthy Aging, Vitality, Healthy Adult Participants
Interventions: Apple Extract, Placebo; Dietary Supplement · Other
Lead sponsor: Nutraland USA, Inc.; Industry
Eligibility: 45 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stress Disorders, Post-Traumatic, Pain, Chronic
Interventions: Mantram Repetition Program for PTSD + Pain, Health Education while Living with Pain; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: San Diego, California

Conditions: GERD, Hiatal Hernia, Heartburn, Paraesophageal Hernia, Gastroesophageal Reflux
Interventions: Preoperative workup without high-resolution esophageal manometry, Standard preoperative workup with high-resolution esophageal manometry; Procedure
Lead sponsor: McMaster University; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Coronary Artery Disease, Coronary Stent Occlusion
Interventions: Prolonged inflation, Rapid inflation; Other
Lead sponsor: Central Arkansas Veterans Healthcare System; Federal
Eligibility: 19 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Ovarian Cancer
Interventions: Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib, Debulking Procedure; Drug · Biological · Procedure
Lead sponsor: Kalinski, Pawel, MD, PhD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Achilles Injuries Tendon, Achilles Tendinopathy (AT), Achilles Tendinitis, Left Leg, Achilles Tendinitis, Right Leg, Achilles Tendon Pain, Achilles Tendonitis
Interventions: Platelet Rich Plasma, Extracorporeal Shockwave Therapy, Sham PRP, Sham ESWT; Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Spasticity
Interventions: XIAFLEX Collagenase injection; Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Optic Nerve Injuries, Sellar Tumor, Skull Base Neoplasms
Interventions: Optic Nerve Stimulation; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
Interventions: Sodium Acetate, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Retinal Detachment Rhegmatogenous
Interventions: Intravitreal 100% C3F8 Injection, Pars plana vitrectomy or pars plana vitrectomy with scleral buckle; Procedure
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Overactive Bladder, Parkinson Disease
Interventions: mirabegron, Exercise-based behavioral therapy; Drug · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Decatur, Georgia • Philadelphia, Pennsylvania • Salt Lake City, Utah

Conditions: Post-Acute COVID-19 Syndrome
Interventions: Keytruda; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 110 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: Trimethoprim Tablets; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Medullary Thyroid Cancer
Interventions: Not listed
Lead sponsor: Power Life Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic
Interventions: Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3, PROSTest; Drug · Device · Diagnostic Test
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions: Nemtabrutinib; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Continuous Assessment of Brain Blood Perfusion in Subarachnoid Hemorrhage Patients Using Near-Infrared Spectroscopy (NIRS)

Terazosin for Dementia With Lewy Bodies

Elucidating the Central Mechanisms of Action for Green Light Therapy in Managing Chronic Pain

HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking

Paired Spinal Cord and Peripheral Nerve Stimulation to Recover Hand Function in SCI

Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

Low Intensity Focused Ultrasound in ASD

SleepSMART for Veterans With Insomnia and Mild Cognitive Impairment

Evaluation of AppleX™ Apple Extract on Anti-Inflammatory and Healthy Aging Effects

Mantram Repetition Versus Health Education for Veterans With PTSD and Chronic Pain

Antireflux Surgery Without Preoperative Esophageal Manometry

Rapid Inflation/Deflation Compared With Prolonged High-Pressure Balloon Inflation

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

Extracorporeal Shockwave Therapy and Platelet-Rich Plasma for Midportion Achilles Tendinopathy

Collagenase Injection for Spasticity Management

Optic Nerve Stimulation To Prevent Visual Deficits After Endoscopic Cranial Approaches

Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients

Use of Preoperative Gas in Eyes With Macula-off Rhegmatogenous Retinal Detachment (RRD)

Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease

Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

Folate Study in Men With Advanced Prostate Cancer

A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor